{"transactions":[{"id":4631407,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Stock option (right to buy)","published_at":"2026-10-05T23:58:55.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service."}],"balance_after":133334,"derivative":{"exercise_price":21.63,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001193125-26-414688","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526414688/ownership.xml","form_type":"4"}},{"id":4631406,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-10-05T23:58:55.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":5147,"price":116.585,"value":600062.995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":3946,"source":{"system":"sec-edgar","filing":"0001193125-26-414688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526414688/ownership.xml","form_type":"4"}},{"id":4631405,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-10-05T23:58:55.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":2086,"price":115.7298,"value":241412.3628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":9093,"source":{"system":"sec-edgar","filing":"0001193125-26-414688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526414688/ownership.xml","form_type":"4"}},{"id":4631404,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-10-05T23:58:55.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":114.5205,"value":125972.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":11179,"source":{"system":"sec-edgar","filing":"0001193125-26-414688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526414688/ownership.xml","form_type":"4"}},{"id":4631403,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-10-05T23:58:55.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":true,"shares":8333,"price":21.63,"value":180242.79,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":12279,"source":{"system":"sec-edgar","filing":"0001193125-26-414688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526414688/ownership.xml","form_type":"4"}},{"id":3984,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Stock option (right to buy)","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":58333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service."}],"balance_after":141667,"derivative":{"exercise_price":21.63,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":58333},"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3983,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":1225,"price":115.4395,"value":141413.3875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":4242,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3982,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":5621,"price":114.5779,"value":644042.3759,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":5467,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3981,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":1606,"price":113.7187,"value":182632.2322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":11088,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3980,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":974,"price":112.3966,"value":109474.2884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":12694,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3979,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":1537,"price":111.3733,"value":171180.7621,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":13668,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3978,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":23770,"price":110.7004,"value":2631348.508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":15205,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3977,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":23600,"price":109.3506,"value":2580674.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":38975,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3976,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":58333,"price":21.63,"value":1261742.79,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":62575,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3975,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-02","kind":"tax_withholding","planned":true,"acquired":false,"shares":102,"price":113.38,"value":11564.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The closing price on September 1, 2026 was used to calculate the withholding obligation."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":4242,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3974,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-01","kind":"grant","planned":true,"acquired":true,"shares":138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":4344,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}},{"id":3973,"issuer":{"id":2620,"kind":"organization","name":"CORCEPT THERAPEUTICS INC","symbol":"CORT"},"owners":[{"id":2621,"kind":"person","name":"Vieira Roberto Wandenkolk","position":1,"cik":"0002150104","reported_name":"Vieira Roberto Wandenkolk","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Oncology"}}],"security":"Common Stock","published_at":"2026-09-04T01:02:52.000Z","date":"2026-09-01","kind":"grant","planned":true,"acquired":true,"shares":138,"price":113.38,"value":15646.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person purchased shares (\"Purchase Plan Shares\") of the Issuer's common stock pursuant to a purchase plan (\"Purchase Plan\") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements."}],"balance_after":4206,"source":{"system":"sec-edgar","filing":"0001193125-26-382456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2150104/000119312526382456/ownership.xml","form_type":"4"}}]}